Retatrutide vs Tirzepatide
Compare Retatrutide (triple agonist) and Tirzepatide (dual agonist), two next-generation incretin peptides. Understand how the addition of glucagon receptor activation changes the metabolic research landscape.
Retatrutide
GLP-1 / Weight Management
Tirzepatide
GLP-1 / Weight Management
Side-by-Side Comparison
Triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors; glucagon activation increases energy expenditure and hepatic lipid oxidation
Dual GIP and GLP-1 receptor agonist that activates both incretin pathways for synergistic insulin secretion, glucagon suppression, and appetite reduction
GLP-1 + GIP + Glucagon (GCGR) receptors (triple agonist)
GLP-1 + GIP receptors (dual agonist)
~6 days (once-weekly dosing)
~5 days (once-weekly dosing)
Once weekly
Once weekly
Obesity with extreme weight loss potential (>24% in trials), type 2 diabetes, triple incretin receptor pharmacology, hepatic fat reduction and NASH, energy expenditure and thermogenesis
Type 2 diabetes with superior HbA1c reduction, obesity treatment, dual incretin pharmacology, cardiovascular and metabolic syndrome research
4731.41 Da
4813.45 Da
$41.95/vial (5mg)
$14.95/vial (2mg)
Triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors; glucagon activation increases energy expenditure and hepatic lipid oxidation
Dual GIP and GLP-1 receptor agonist that activates both incretin pathways for synergistic insulin secretion, glucagon suppression, and appetite reduction
GLP-1 + GIP + Glucagon (GCGR) receptors (triple agonist)
GLP-1 + GIP receptors (dual agonist)
~6 days (once-weekly dosing)
~5 days (once-weekly dosing)
Once weekly
Once weekly
Obesity with extreme weight loss potential (>24% in trials), type 2 diabetes, triple incretin receptor pharmacology, hepatic fat reduction and NASH, energy expenditure and thermogenesis
Type 2 diabetes with superior HbA1c reduction, obesity treatment, dual incretin pharmacology, cardiovascular and metabolic syndrome research
4731.41 Da
4813.45 Da
$41.95/vial (5mg)
$14.95/vial (2mg)
Which Is Right for Your Research?
Choose Retatrutide for triple-receptor research exploring maximum metabolic impact including energy expenditure via glucagon receptor activation. Choose Tirzepatide for well-established dual-agonist protocols with more extensive clinical data.